- Journalists Shed Light on Deadly Hantavirus Outbreak and a Crisis in the Nation’s ERs
- Is the horizon still bright for orthodontists?
- The Make America Healthy Again Movement Comes for Hospital Food
- What’s driving physicians to early retirement
- Why Tenet’s CEO says ASCs keep choosing USPI
- 12 recent hospital, health system president exits
- Hospitals embrace rapid opioid treatment in fentanyl era: Study
- Texas systems open 200-bed behavioral health center
- 32 health systems spending $5B on cancer care
- Sanford, North Memorial planned combination adds to Minnesota healthcare deal wave
- Lone Peak Dental Group acquires Arizona practice
- Inside Northwestern Medicine’s battle against surgeon burnout
- UT Austin launches Epic ahead of new academic medical center
- Ohio system names COO
- Buy, sell or fight: The new calculus of health system growth
- OpenAI’s growing healthcare footprint
- Tennessee optometrist pleads guilty to $6.9M Medicare fraud
- Why Cook County Health’s Medicaid coverage loss strategy is drawing attention
- Akron Children’s chosen for former Ohio college campus site
- Surgery Partners doubles down on orthopedics, robotics as total joint growth hits 14.6%
- The growing war over Anthem’s out-of-network penalty policy
- 3 PDS Health headlines to know in 1 week
- Remarks at the Conference on Financial Market Regulation
- Could ASCs help cardiology move past its ‘breaking point’?
- 3 programs expanding the anesthesia workforce in 2026
- Dad Jokes: Remarks at the 13th Annual Conference on Financial Markets Regulation
- UVM Health targets $300M in cuts, outpatient overhaul amid $280M deficit
- Maine behavioral health provider cites industry pressures in merger
- Dentists opening practices in 1 month
- The Aspen Group names new chief commercial officer
- RFK Jr. Launches Plan To Curb Antidepressant 'Overprescription'
- Georgia mental health provider adds after-hours outpatient program
- AI-augmented behavioral health provider Theris launches out of stealth
- 5 data breaches, settlements impacting cardiology
- Maine hospital adds stroke prevention, cardiac imaging services
- As new tech, AI sweeps the marketing world, Eversana Intouch’s new CEO is ‘comfortable in the gray’
- Sanford Health unveils deal to integrate Minnesota-area North Memorial Health, invest $600M
- Trump plans to fire FDA chief Marty Makary: report
- Trump plans to fire FDA chief Marty Makary: report
- Oregon governor signs behavioral health workforce expansion bills amid shortage
- Remarks at the Special Competitive Studies Project AI+ Expo
- Lawmakers, former FDA leaders and more rally behind mifepristone as Supreme Court weighs telemedicine access to abortion pill
- 5 DSOs making headlines
- Plant-Based Foods May Help Lower Risk of High Blood Pressure
- The ACA exchanges dominated Q1 earnings calls. Here's what payer, health system execs had to say
- Targeted Protein Degradation and Novel Modalities: Getting on the Frontline
- Gilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory'
- Capricor Therapeutics files breach-of-contract lawsuit against US partner NS Pharma
- Op-ed: It's time to make more strategic bets on AI in healthcare
- Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild
- Super Shoes Might Increase Risk Of Running Injuries, Study Says
- TV, Movies Offer Flawed Depictions Of Autism, Add To Delayed Diagnosis, Study Says
- Opioid OD Survivors Have Triple Rate Of Repeat Overdoses Than Previously Estimated
- Revisiting Pharma’s tariff reality
- A New Medicare Option For Weight Loss Drugs: What Older Americans Should Know
- Exposure Therapy Can Successfully Ease Peanut Allergies
- Listen: A Federal Agency Is After Workers’ Health Data, and Critics Are Alarmed
- In California Governor Race, Single-Payer Is a Litmus Test. There’s Still No Way To Pay for It.
- AbbVie’s Skyrizi beats out J&J’s Tremfya in April drug ad spending leaderboard
- Johnson & Johnson launches ‘Generation Fine’ depression project
- Pre-launch efforts linked to lasting drug awareness edge: report
- GSK tees up a Modern Family for meningitis messaging
- NYC invests $12M in overdose recovery workforce
- Aspen Dental to pay $2M to settle allegations of violating corporate dentistry laws
- Texas dental practice relocates into 6K-square-foot facility
- Medit launches global orthodontics division, acquires California training institute
- Pennsylvania enacts dental faculty bill
- Cruise Ship Hantavirus Outbreak Kills 3 as WHO Says Risk Is Low
- How policy, reimbursement incentives, could help healthcare address its climate footprint
- Remarks at the 13th Annual Conference on Financial Market Regulation
- 5 best practices for financially integrating behavioral health
- Fierce Pharma Asia—Summit’s surprise interim trial miss; UCB’s $2B Candid buy; J&J’s CAR-T cuts
- Amazon Pharmacy to offer home delivery for Novo Nordisk's Ozempic pill
- New York expands behavioral health data access in EHRs
- Staffing firm Cross Country Healthcare to be acquired by Knox Lane for $437M
- New Hampshire to receive $29.5M in Purdue opioid settlement
- Behavioral health leaders counter HHS ‘overprescribing’ narrative
- Clover Health's MA membership grows 51% year-over-year
- New Study Suggests The Brain Can Continue Learning While In An Unconscious State
- Health Tech Weekly Rundown: Tether rolls out medical AI for phones, wearables; Medaptus launches operational ‘command center’
- Pennsylvania sues Character.ai over AI chatbot allegedly presenting itself as licensed medical professional
- Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
- FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
- Every 1,000 Steps After Surgery Cuts Complication Risk, Study Finds
- Bullying and Politics Fuel Suicide Risk for LGBTQ+ Teens and Young Adults, Survey Finds
- Head Impacts May Disrupt Gut Health Even Without Concussion
- Class of Migraine Drug, CGRP Inhibitors, Has Added Benefit: Reduced Glaucoma Risk
- States Eye Aid to Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
- That Discount at the Pharmacy Counter May Pack Hidden Costs
- Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
- Hims & Hers debuts its first AI care agent to interpret biomarker lab results
- Alnylam rebuked by FDA over efficacy claims on Amvuttra website
- Insulet CEO details ‘Scrubs’ device promotion win as it boosts awareness, education drive
- Oscar Health's profit hits $679M, membership rises in Q1
- Joint Commission, NACHC partner on training, new accreditation for community health centers
- Ardent Health touts outpatient growth, checked labor spend during hectic Q1
- FDA Authorizes Fruit-Flavored Vapes for Adults
- Sanofi asks to pull Tzield bid from FDA's controversial CNPV program: report
- FDA rolls out 1-day assessment pilot in bid to refocus inspection resources
- Nearly 8 in 10 employers say GLP-1 coverage drives up benefit costs: Business Group on Health
- Edibles + Alcohol Combo Poses Driving Risks Missed by Sobriety Tests
- Leapfrog Group's latest safety grades have far fewer low scores since removal of non-participating hospitals
- VR Training Helps Autistic People Navigate Police Encounters
- Novo CEO cites pricing 'sweet spot' as Wegovy pill debuts with $355M quarter
- Weight Loss Surgeries Fall More Than 20% As Patients Turn To GLP-1 Meds, Experts Say
- FDA blocks publication of COVID, shingles vaccine safety studies: NYT
- Bayer diagnoses how to build trust in cell and gene therapies
- Amwell boasts higher than expected renewals, retention despite Q1 revenue decline
- First Psych Ward Stay Signals Long-Term Mental Health Struggles For Nearly All Patients
- Why Melatonin Shouldn't Be A Bedtime Go-To For Kids
- Children Living Near Gas Stations Have Higher Cancer Risk, Study Finds
- The timing is right for psychedelics manufacturer Optimi Health's IPO
- HHS' Healthy Food Agenda Puts Hospitals On Notice About Patients' Meals
- A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
- Trump’s Drug Strategy Aims To Bolster Addiction Services — Despite Gutting of Government Support
- Inside the gaps in fertility and surrogacy systems
- CVS execs say company on track to meet MA margin goals by 2028
- Facilitating Access to Trump Accounts
- Fixing Failures to Communicate
- Hinge Health lifts 2026 outlook after strong Q1 as it expands to new conditions
- For nonprofit hospitals, pricey management consultants haven't yielded better performances: study
- Supreme Court Issues Stay, Keeping Abortion Pill Mifepristone Available by Mail For Now
- Statement on Proposing Release for Semiannual Reporting
- Quarterly Questions: Statement on the Proposed Amendments to Allow Semiannual Reporting
- Statement on Proposing Semiannual Reporting
- Wellstar partners with BD to implement AI-driven medication management system
- Listen to the Latest ‘KFF Health News Minute’
- Newer Migraine Drugs Reduce Headache Days With Fewer Side Effects
- New Drug Combo Effective Against Treatment-Resistant IBD, Trials Show
- New Warning Labels Might Help People Cut Back On Drinking
- Ozempic Can Curb Cravings in Alcohol Use Disorder, Landmark Trial Finds
- US on the Brink of Losing Measles-free Status, Study Warns
- Delays in Visa Program Threaten Doctor Placements in Underserved Areas
- States Eye Aid To Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
- Supreme Court Puts Brakes on Abortion Pill Restrictions
- FDA Green Lights Expanded Access to Pancreatic Cancer Drug, Daraxonrasib
- Online Misinformation Adding To Americans' Skin Cancer Risk, Survey Finds
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Social Media Videos, Easy Access Raise Risk of Teen Inhalant Use
- Staff Statement Regarding Pooled Employer Plans
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- 'Fitspirational' Posts Can Be More Harmful Than Motivational, Review Concludes
- Parents’ Stress Tied to Children’s Mental Health, New Survey Finds
- Surgeon Multitasking Increases Death Risk Of Organ Transplantees
- When Natural Disasters Strike, Another Crisis Hits Those Recovering From Opioid Addiction
- FDA Recalls Several Ghirardelli Powdered Beverages Over Potential Contamination
I have promoted OTC status for Ivermectin since early 2022, when I pointed out that raging social media warriors were wrong to demand hospitals include it in protocols. The large meta-study available at the time did not include data from late (hospital) treatment. However, it did demonstrate that
... early treatment allowed most to avoid the hospital entirely.
In addition to early treatment success, people know their own symptoms and results best. When an endemic disease has safe treatment, it’s common sense to self-treat and avoid hospitals.
MedPage Today reviews states doing just that.
https://www.medpagetoday.com/special-reports/features/116436
These States Now Allow OTC Ivermectin, and More May Follow
— Four have passed new laws, and at least nine have legislation in the works
by Rachael Robertson | July 9, 2025
A handful of states have passed legislation allowing ivermectin to be sold and purchased over-the-counter (OTC) -- and other state legislatures have their sights set on doing the same.
During the pandemic, rampant misinformation drew attention to the antiparasitic as a treatment for COVID, though research continues to show it is not effective against the disease.
Ivermectin tablets are FDA approved at specific doses for treating some parasitic worms, as are topical formulations for some skin conditions and head lice, but neither are FDA approved for preventing or treating COVID. Despite this, an increasing number of states are making it easier to get ivermectin and protecting pharmacists from lawsuits and discipline by licensing boards. None of the laws have information about dosing.
Currently four states -- Tennessee, Arkansas, Idaho, and Louisiana -- have passed OTC ivermectin laws.
In April 2022, Tennessee passed SB 2188/HB 2746, becoming the first state to make ivermectin available OTC. The legislation authorizes "ivermectin suitable for human use" to be sold or purchased OTC "without a prescription or consultation with a pharmacist or other healthcare professional." For 3 years, Tennessee was the only state to have OTC ivermectin.
Then on March 25 of this year, Arkansas passed SB 189, now Act 396. Weeks later, on April 14, Idaho passed similar OTC ivermectin legislation, SB 1211.
Louisiana SB 19, now Act 464, went into effect on June 20, making it the latest state to make ivermectin available OTC. This law specifies that a pharmacist can dispense ivermectin to adults "pursuant to a standing order issued by a healthcare professional with prescriptive authority" and requires the pharmacist to provide the patient with information on indications and contraindications as well as a screening risk assessment tool. For this service, the pharmacy may charge an administrative fee. Ralph Abraham, MD, the state's surgeon general, backed the bill.
In addition to these, other states have bills moving through their legislatures:
Texas
Just this week, 20 Texas House Republicans asked Gov. Greg Abbott (R) to add the reclassification of ivermectin as OTC -- under proposed HB 3219 -- to the agenda for a special session set to begin later this month. Some of these lawmakers have connected the issue to medical freedom.
New Hampshire
A bill with a unique two-fold approach, SB 119, was introduced in May, which lumps together ivermectin access with an unrelated Medicaid provision. The bill would allow pharmacists to follow a standing order from a physician, physician assistant, or advance practice registered nurse to dispense ivermectin alongside an information sheet on side effects. Also included are various protections against disciplinary action for these healthcare professionals.
The paired Medicaid provision "directs pharmacists to dispense brand name drugs to Medicaid beneficiaries when the brand name drug is on the department of health and human services preferred drug list."
North Carolina
The Ivermectin Access Act, or HB 618, was proposed in April 2025. This legislation would direct the state health director "to issue a statewide standing order to allow pharmacists to dispense ivermectin without prescription" as well as "providing immunity from civil or criminal liability" for both the director and any pharmacist who dispenses ivermectin.
Pennsylvania
Also in April, a lawmaker proposed SB 601, which would amend the state's Pharmacy Act to make ivermectin available OTC.
Georgia
In March, SB 366 was first proposed to amend parts of the Official Code of Georgia Annotated related to controlled substances and to pharmacists and pharmacies. This would "provide for ivermectin as an over-the-counter medication in this state" and "remove ivermectin from the definition of, exceptions to, and exemptions from dangerous drugs."
Alabama
A lawmaker brought forth HB 278 in February, which would "permit a physician, a physician assistant, or a certified registered nurse practitioner to give a pharmacist a standing order that has been approved by the State Board of Pharmacy to dispense ivermectin to individuals without a prescription." The standing order would involve a risk assessment protocol and a standardized information sheet.
It also has various disciplinary protections for pharmacists and forbids them from participating in "any program or accept anything of value that induces the healthcare provider or pharmacist to affirmatively commend or endorse the use of ivermectin to an individual or the public."
If passed, the legislation would take effect in October of this year.
West Virginia
SB 614 was also introduced in February. The bill would authorize pharmacists to dispense ivermectin without a prescription or consultation and protect them from liability from damages or licensing board discipline.
Missouri
SB 744, which would make both ivermectin and hydroxychloroquine available OTC, was introduced in February, though it has not made much progress. A similar bill, HB 2581, was proposed in January 2024, but never passed.
South Carolina
HB 3916, proposed in February, also aims to make both ivermectin and hydroxychloroquine available without prescription or consultation.
Axios's Ivermectin update couldn't be more biased, but hang in there: the good stuff is toward the end.
https://www.axios.com/local/phoenix/2026/02/02/ivermectin-over-the-counter-arizona-bill
Arizona bill would let people buy ivermectin without a prescription
Jessica Boehm, Kim Bojórquez | Feb. 2, 2026
Republicans in Arizona and nationwide are trying to make it easier to get ivermectin, the controversial anti-parasitic drug widely used to treat livestock but embraced by some as a treatment during the pandemic.
Why it matters: Ivermectin was promoted largely by conservatives as a "miracle" drug amid the COVID-19 pandemic, despite multiple medical studies that found it isn't effective at treating the novel coronavirus, and repeated warnings from leading medical institutions outside of FDA-approved use. Still, it has persisted as an alternative treatment for COVID.
The drug is approved for human use to treat parasitic worms and conditions such as head lice and rosacea, per the FDA.
State of play: Arizona State Rep. Nick Kupper (R- Surprise) sponsored a bill to make ivermectin that's formulated for human use available over the counter without a prescription or medical consultation.
The measure has not yet been scheduled for a hearing.
The intrigue: Kupper, who did not respond to Axios' interview request, told Arizona's Family he introduced the bill in response to constituent interest in the drug, and he dismissed health concerns.
"Think about how many energy drinks we drink every day. There's caffeine in coffee or vaping or smoking cigarettes. … These are all things that you don't need a prescription to get," Kupper told Arizona's Family.
The other side: Doctors and toxicologists, including the American Medical Association, American Pharmacists Association and American Society of Health-System Pharmacists, have widely cautioned against ivermectin use.
During the pandemic, the Banner Poison and Drug Information Center in Phoenix and Arizona Poison and Drug Information Center in Tucson said they received several calls concerning ivermectin exposure.
"Higher doses can cause significant illness in humans," Daniel Brooks, then the medical director of the Banner Poison and Drug Information Center, said in a 2021 statement.
Reality check: Will Humble, executive director for the Arizona Public Health Association, told Axios the bill is "performative."If it reaches Democratic Gov. Katie Hobbs' desk, she'll almost certainly veto it, he said.
Even so, it's unlikely that national chain pharmacies would stock the drug — even if given state approval — because of federal legal and licensure risks.Plus, people who really want ivermectin can already get it at many of Arizona's livestock supply stores without a prescription, because it's widely used for deworming horses.
Zoom out: At least five states have already legalized ivermectin sales without a prescription: Texas, Tennessee, Arkansas, Idaho and Louisiana.Republican Utah state Rep. Trevor Lee introduced a bill in his state, telling Axios it would expand medical freedom and align with Health and Human Services Secretary Robert F. Kennedy Jr.'s "Make America Healthy Again" agenda.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.













